Reset filter
Palabras clave
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
    1. 1.1. Determinación de Elegibilidad
    1. 1.2. Historial médico
    1. 1.3. Examen físico
    1. 1.4. Puntuación de evaluación
    1. 1.5. Diagnóstico aparente
    1. 1.6. Laboratorio
    1. 1.7. Patología / Histología
    1. 1.8. Consentimiento
    1. 1.9. Terapia
    1. 1.10. Informe Operativo
    1. 1.11. Acontecimiento adverso
    1. 1.12. Seguimiento
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

5058 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Pre-Study - NCI Standard Participant Identification Template - 2729615v1.0 - NCI Standard Participant Identification Template

- 20/9/21 - 1 formulario, 2 itemgroups, 11 items, 1 idioma
Itemgroups: Conditional Participant ID Questions, Optional Participant ID Questions
The collection of CDEs used in the Participant ID module. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=46716FCE-3AD1-70D5-E044-0003BA3F9857

Registration - NCI Cooperative Group Registration Form - 2263990v3.0 - NCI Cooperative Group Registration Form

- 17/9/21 - 1 formulario, 6 itemgroups, 37 items, 1 idioma
Itemgroups: Registration Header, Protocol Administration, Patient Demographics/Pre-Treatment Characteristics, Certification of Eligibility, Protocol Design, Initial Patient Consent for Specimen Use
NCI Cooperative Group Registration Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D8879517-2F12-048F-E034-0003BA12F5E7

Pre-Study - PRIOR THERAPY SUPPLEMENT - 2394210v1.0 - PRIOR THERAPY SUPPLEMENT

- 9/1/15 - 1 formulario, 2 itemgroups, 11 items, 1 idioma
Itemgroups: PRIOR THERAPY SUPPLEMENT, COMMENTS
Prior Therapy form for C3D 3.12 Adopters Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FF07B012-CA3F-1CA3-E034-0003BA3F9857

Pre-Study - NCI Standard Registration Template - 2745056v1.0 - NCI Standard Registration Template

- 20/9/12 - 1 formulario, 3 itemgroups, 18 items, 1 idioma
Itemgroups: Mandatory Registration Questions, Conditional Registration Questions, Optional Registration Questions
The collection of CDEs used in the registration module. Registration consists of the registering institution applying for entry of a consented participant into a specific research study by conveying designated registration information to a central facility that is in charge of accepting participants into the study. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4C056DEC-99CB-35E0-E044-0003BA3F9857

Breast Cancer NCT00433589 Treatment - Endocrine therapy - 2498727v1.0 - Endocrine therapy

- 9/1/15 - 1 formulario, 3 itemgroups, 14 items, 1 idioma
Itemgroups: Header, Endocrine therapy, Footer Module
Endocrine therapy Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=19677A9A-FFBD-2E6F-E044-0003BA3F9857

Breast Cancer Adverse Event NCT00382070 - rade 2 and 3 Adverse Event Report Breast Cancer NCT00382070 NSABP B-42

- 20/9/21 - 1 formulario, 2 itemgroups, 9 items, 1 idioma
Itemgroups: Header, Adverse event
NSABP Protocol B-42 - Grade 2 and 3 Adverse Event (AE) Report Form Worksheet Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer NCT00382070 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=17ADF05F-DB75-341D-E044-0003BA3F9857

Vital Signs Anal Cancer NCT00324415

- 31/7/15 - 1 formulario, 3 itemgroups, 13 items, 1 idioma
Itemgroups: Header module, Vital Signs, Comments
Anal Cancer NCT00324415 On-Study - AMC-045 Vital Signs Form (F20) - 2937179v1.0 Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy in Treating Patients With HIV and Stage I, Stage II, or Stage III Anal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7285E88F-E0EF-C8EB-E040-BB89AD437ABB

Eligibility Breast Cancer, Colorectal Cancer NCT01493336

- 30/9/19 - 1 formulario, 2 itemgroups, 18 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours; ODM derived from: https://clinicaltrials.gov/show/NCT01493336

Colorectal Cancer Non-Protocol Therapy NCT00303628 - Non-Protocol Therapy Colorectal Cancer NCT00303628 E5204

- 25/3/15 - 1 formulario, 2 itemgroups, 25 items, 1 idioma
Itemgroups: Header, Non-Protocol Therapy
E5204 Non-Protocol Therapy Form Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer NCT00303628 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=089B4967-A7D1-3905-E044-0003BA3F9857

Breast cancer NCT00053898 - PATHOLOGIST'S REPORT FORM (NSABP B-35 NCT00053898)

- 22/3/15 - 1 formulario, 2 itemgroups, 24 items, 1 idioma
Itemgroups: Header, Pathology report
NSABP PROTOCOL B-35 PATHOLOGIST'S REPORT FORM Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy NCT00053898 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A01C3BB9-FE93-4CD3-E034-080020C9C0E0

Eligibility Breast Cancer, Early Breast Cancer NCT02443467

- 20/1/17 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02443467

Colorectal cancer metastases (NCT00268463) - Quality of Life Form Colorectal Cancer (NSABP C-09 NCT00268463)

- 20/9/21 - 1 formulario, 8 itemgroups, 94 items, 1 idioma
Itemgroups: Header, Treatment satisfaction, PHYSICAL WELL-BEING, Social and family well being, EMOTIONAL WELL-BEING, Functional Health, ADDITIONAL CONCERNS, Activity
NSABP Protocol C-09: Quality of Life Form Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer NCT00268463 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FC7E0FCB-064A-58CD-E034-0003BA3F9857

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial